Jupiter Neurosciences Prices $2M Registered Direct Offering at $6.50/Share
JUNS sits 19% above its 52-week low of $4.56 on elevated volume (54× avg).
Summary
Jupiter Neurosciences priced a $2 million registered direct offering at $6.50 per share, netting about $1.74 million for working capital. The raise comes amid a going concern warning and a Nasdaq delisting deadline of August 25, 2026.
Key Events · Financing and Capital Events · JUNS
-
Registered Direct Offering Priced
307,692 shares offered at $6.50 per share for gross proceeds of $1,999,998; net proceeds to the company of approximately $1.74 million after placement agent fees and expenses.
-
Dilution Impact
Offering increases outstanding shares from 912,909 to 1,220,601 — roughly 25% dilution to existing holders. New investors face immediate dilution of $3.73 per share based on pro forma net tangible book value.
-
Going Concern and Nasdaq Deadline
Filing reiterates management's substantial doubt about continuing as a going concern and notes the company must regain Nasdaq compliance by August 25, 2026 — one day after expected closing.
-
Placement Agent Terms
D. Boral Capital LLC engaged as exclusive placement agent with a 7.0% cash fee ($139,999.86) plus expense reimbursement up to $75,000, and a 60-day tail fee on introduced investors.
Analysis · JUNS · Life Sciences
Jupiter Neurosciences is raising approximately $1.74 million in net proceeds through a registered direct offering of 307,692 shares at $6.50 per share. The offering price sits above the $5.17 last reported sale price on August 20, 2026, but the company remains under severe financial strain — its most recent 10-Q disclosed a going concern warning, and the filing itself states current cash is insufficient to fund operations for the next twelve months. The capital extends the runway but adds roughly 25% to the outstanding share count, diluting existing holders at a time when the company is also fighting to maintain its Nasdaq listing with an August 25, 2026 compliance deadline.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUNS was trading at $5.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $4.56 to $137.96. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.